[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-idiopathic-thrombocytopenic-purpura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-idiopathic-thrombocytopenic-purpura":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100574282","special-drug-use-results-survey-for-long-term-use-fostamatinib-100574282",false,"NCT06757257","Special Drug Use-results Survey for Long-term Use (Fostamatinib)","Inclusion Criteria:\n\n* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.","ALL",{"count":17,"type":18},149,"ESTIMATED","18 Months","OBSERVATIONAL","The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.",[23],"Chronic Idiopathic Thrombocytopenic Purpura","RECRUITING","2024-12-26",{"date":27,"type":28},"2025-01-03","ACTUAL",{"date":30,"type":28},"2023-05-29",{"date":32,"type":18},"2028-09-30",{"name":34,"class":35},"Kissei Pharmaceutical Co., Ltd.","INDUSTRY"]